Big Pharma spent decades and billions trying to solve osteoarthritis, a $500B market they’ve never cracked.

Thankfully, Cytonics figured out why they keep failing: joints are attacked by multiple culprits at once, and Big Pharma only ever went after one at a time.

So Cytonics discovered a way to get them all, creating the first therapy with the potential to actually address the root cause of osteoarthritis at the molecular level. It’s already proven across 10,000+ patients. Now, they’re pushing toward FDA approval on a 200% more potent version that can be manufactured at scale.

The first human safety trial is already complete with zero adverse events. If approved, the more than 500M osteoarthritis patients worldwide could have their long-needed solution.

Big Pharma created this opening. Now Cytonics is prepared to seize it.

And until March 26, you can claim exclusive investor bonuses and maximize your early-stage Cytonics stake.

Invest in Cytonics Now

Introduction

V is for Value.
In recent weeks, we identified where the market was mispricing opportunity—and positioned accordingly.

V is for Value Creation.
It’s not just about spotting the setup. It’s about executing in a way that compounds returns while managing risk when the backdrop is less certain.

V is for V-Bottom.
A confluence of stretched positioning, improving internals, and key technical triggers helped define a tradeable low—rewarding those willing to step in when it felt most uncomfortable.

V is for Vision.
By integrating DeMark signals, cross-asset inputs, and market structure, we maintained a forward-looking framework that stayed ahead of consensus.

Taken together, this is how we’ve navigated the recent environment—turning disciplined analysis into actionable outcomes.

So we’ll ask the question: did you listen?

Being right in this business is hard. Being consistently right is even harder. We believe we continue to deliver both—and that’s worth acknowledging.

As a reminder, in our 3/22 report we told readers to Buy the Panic. Since then, the SPX has rallied ~11% off the lows and printed a fresh all-time high on Wednesday.

That’s not just a bounce.

That’s a textbook—albeit rare—V-bottom.

To be fair, we were not explicitly calling for new all-time highs. However, we did outline a 6920–6940 upside objective contingent on confirmation of the inverse head-and-shoulders pattern.

As we wrote on 4/5—more than 400 SPX points ago:

We outlined a similar setup for the Nasdaq 100 (NDX), but you get the point. We identified the pattern, laid out the roadmap, and for those who followed it—it was raining alpha.

And it didn’t stop there.

In that same report, we flagged oil as being near a top—an outcome that would serve as a tailwind for equities and help fuel the breakout.

As noted in our 4/5 report:

We went a step further, identifying ~87 as the first key downside level likely to attract buyers. As outlined in our 4/8 report:

So where did oil ultimately find support and reverse on Tuesday night? Right at ~87—precision matters.

We highlighted across multiple reports that the USD (DXY) was a key macro signal for interpreting the geopolitical backdrop. In our 4/5 report, we noted that momentum was waning into the recent highs—a classic precursor to a failed breakout.

That loss of momentum served as a leading indicator for a potential “ceasefire,” with the subsequent gap down below the uptrend line providing confirmation.

We reinforced this view in our 4/8 report, where we wrote:

We reinforced this guidance in our most recent report, emphasizing that a failure to reclaim would serve as a bullish signal for equities.

As outlined in our 4/12 report:

When we conduct our analysis, we are constantly searching for confluence. When enough evidence begins to align, we make the call.

That was the case in late March.

Two of the key reasons we were confident in buying the market weakness were the reversal signals emerging from two critical sectors.

As we wrote in our 3/29 report, Financials (XLF) and Consumer Discretionary (XLY) were positioned to turn:

For those who acted on our analysis and allocated to those sectors following the report, the outcome has been meaningful.

XLF is up ~10%.

XLY is up ~12% since the DeMark signal printed.

Lastly, our weekend report centered on whether the market was experiencing a “dead cat bounce.” We were emphatic in our view—it was not. Today’s V-shaped move to a new all-time high reinforces that conclusion.

The lesson is simple: follow price, not headlines. If you were reacting to the news flow alone, you likely missed one of the more powerful moves we’ve seen in recent months.

Our objective is straightforward—identify major inflection points, assess the strength of the trend, and keep our readers aligned with it for as long as the signals support the move.

With that in mind, let’s turn to the charts to assess what comes next.

For our freemium subscribers—if you believe this type of analysis and consistent alpha generation can add value to your process, we encourage you to give the research a try. There’s no obligation, and you can unsubscribe at any time.

At ~$1/day, the value proposition speaks for itself.

To mark our recent calls, we’re offering a limited 24-hour window to upgrade—20% off our annual subscription.

Access starts below.